While semaglutide and tirzepatide are the most popular of the GLP-1 drugs at the moment, some other medications in this class include liraglutide and dulaglutide
For the peptide industry, the implications are enormous: Increased pharmaceutical investment Accelerated peptide innovation Greater public awareness Expansion of metabolic research New generations of multi-pathway therapeutics The peptide era is no longer emerging
Coskun et al., LY3437943, a novel triple glucagon, GIP, and GLP- 1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept, Cell Metab., vol
For many individuals, the initial dosage may still leave persistent hunger levels that hinder weight management progress
That makes native IGF-I awkward as an experimental tool, because in any system containing serum or secreted IGFBPs the concentration a researcher adds is not the concentration the receptor sees